BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 30012320)

  • 21. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Chan YH; Lee HF; Chao TF; Wu CT; Chang SH; Yeh YH; See LC; Kuo CT; Chu PH; Wang CL; Lip GYH
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):701-710. PubMed ID: 31745687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry.
    Shiozawa M; Koga M; Inoue H; Yamashita T; Yasaka M; Suzuki S; Akao M; Atarashi H; Ikeda T; Okumura K; Koretsune Y; Shimizu W; Tsutsui H; Hirayama A; Nakahara J; Teramukai S; Kimura T; Morishima Y; Takita A; Yamaguchi T; Toyoda K
    Int J Stroke; 2023 Oct; 18(8):986-995. PubMed ID: 37154598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
    Ohshima A; Koyama T; Ogawa A; Zamami Y; Tanaka HY; Kitamura Y; Sendo T; Hinotsu S; Miller MW; Kano MR
    Fam Pract; 2019 Nov; 36(6):685-692. PubMed ID: 31329899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation.
    Goriacko P; Veltri KT
    Eur J Haematol; 2018 May; 100(5):488-493. PubMed ID: 29444357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism.
    Chan YH; Wu LS; See LC; Liu JR; Chang SH; Chao TF; Yeh YH; Kuo CT; Lee HF; Lip GYH
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32009154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
    Fong KY; Chan YH; Yeo C; Lip GYH; Tan VH
    Am J Cardiol; 2023 Oct; 204():366-376. PubMed ID: 37573616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
    Adachi T; Hoshino H; Takagi M; Fujioka S;
    Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Significant Tricuspid Regurgitation.
    Yang Y; Kim M; Kim J; Cho MS; Lee S; Song JM; Kim DH
    J Am Heart Assoc; 2024 Feb; 13(3):e032272. PubMed ID: 38293966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight.
    Lee SR; Choi EK; Park CS; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2019 Mar; 73(8):919-931. PubMed ID: 30819360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin.
    Datar M; Crivera C; Rozjabek H; Abbass IM; Xu Y; Pasquale MK; Schein JR; Andrews GA
    Am J Health Syst Pharm; 2019 Feb; 76(5):275-285. PubMed ID: 30698654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracranial Hemorrhage in Deep Vein Thrombosis/Pulmonary Embolus Patients Without Atrial Fibrillation.
    Lamsam L; Sussman ES; Iyer AK; Bhambhvani HP; Han SS; Skirboll S; Ratliff JK
    Stroke; 2018 Aug; 49(8):1866-1871. PubMed ID: 29991654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
    Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
    J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.